ONPH Stock Overview
An oncology company, develops, manufactures, and commercializes therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oncology Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.18 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 9,900.00% |
| 1 Year Change | 9,900.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9,900.0% | 2.5% | 1.0% |
| 1Y | 9,900.0% | 15.6% | 31.4% |
Return vs Industry: ONPH exceeded the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: ONPH exceeded the US Market which returned 31.4% over the past year.
Price Volatility
| ONPH volatility | |
|---|---|
| ONPH Average Weekly Movement | 154,673.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ONPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ONPH's weekly volatility has increased from 122702% to 154673% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | George Malesek | www.oncology-pharma.com |
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019.
Oncology Pharma Inc. Fundamentals Summary
| ONPH fundamental statistics | |
|---|---|
| Market cap | US$3.87k |
| Earnings (TTM) | -US$15.27k |
| Revenue (TTM) | US$10.21k |
0.0x
P/S Ratio0.0x
P/E RatioIs ONPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONPH income statement (TTM) | |
|---|---|
| Revenue | US$10.21k |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.21k |
| Other Expenses | US$25.48k |
| Earnings | -US$15.27k |
Last Reported Earnings
Mar 31, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ONPH perform over the long term?
See historical performance and comparison